{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:17:26Z","timestamp":1773055046873,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T00:00:00Z","timestamp":1447632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s13181-015-0518-4","type":"journal-article","created":{"date-parts":[[2015,11,16]],"date-time":"2015-11-16T16:13:07Z","timestamp":1447690387000},"page":"64-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The New Kid on the Block\u2014Incorporating Buprenorphine into a Medical Toxicology Practice"],"prefix":"10.1007","volume":"12","author":[{"given":"Timothy J.","family":"Wiegand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,16]]},"reference":[{"issue":"4","key":"518_CR1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/pmt.12.26","volume":"2","author":"W Ling","year":"2012","unstructured":"Ling W, Mooney L, Torrington M. Buprenorphine for opioid addiction. Pain Management. 2012;2(4):345\u201350.","journal-title":"Pain Management"},{"issue":"5","key":"518_CR2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.annemergmed.2003.11.006","volume":"43","author":"KA Sporer","year":"2004","unstructured":"Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med. 2004;43(5):580\u20134.","journal-title":"Ann Emerg Med"},{"issue":"9","key":"518_CR3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2165\/00023210-200620090-00001","volume":"20","author":"SE Robinson","year":"2006","unstructured":"Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs. 2006;20(9):697\u2013712.","journal-title":"CNS Drugs"},{"key":"518_CR4","unstructured":"Control, U.S.D.o.J.O.o.D. Title 21 Code of Federal Regulations Part 1306: Prescriptions. 2015 [cited 2015 7\/18\/2015]."},{"issue":"5","key":"518_CR5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","volume":"10","author":"J Pergolizzi","year":"2010","unstructured":"Pergolizzi J et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428\u201350.","journal-title":"Pain Pract"},{"issue":"8","key":"518_CR6","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.4088\/JCP.13m08725","volume":"75","author":"JF Karp","year":"2014","unstructured":"Karp JF et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785\u201393.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"518_CR7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1049909109341868","volume":"26","author":"RR Induru","year":"2009","unstructured":"Induru RR, Davis MP. Buprenorphine for neuropathic pain\u2014targeting hyperalgesia. Am J Hosp Palliat Care. 2009;26(6):470\u20133.","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"518_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-2999(02)02052-6","volume":"450","author":"PF Kouya","year":"2002","unstructured":"Kouya PF, Hao JX, Xu XJ. Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury. Eur J Pharmacol. 2002;450(1):49\u201353.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"518_CR9","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/pme.12520","volume":"15","author":"D Daitch","year":"2014","unstructured":"Daitch D et al. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087\u201394.","journal-title":"Pain Med"},{"issue":"1","key":"518_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009127009703700106","volume":"37","author":"J Mendelson","year":"1997","unstructured":"Mendelson J et al. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37(1):31\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"518_CR11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","volume":"44","author":"A Elkader","year":"2005","unstructured":"Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"518_CR12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-144-2-200601170-00010","volume":"144","author":"DP Alford","year":"2006","unstructured":"Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127\u201334.","journal-title":"Ann Intern Med"},{"key":"518_CR13","unstructured":"REMS, B.T.f.O.D. BTOD\/REMS. 2015 [cited 2015 7\/15\/2015]."},{"key":"518_CR14","unstructured":"Inc, R.B.P. Suboxone(R) Sublingual Film. 2015 [cited 2015 6\/30\/2015]; Available from: http:\/\/www.suboxone.com\/ ."},{"key":"518_CR15","unstructured":"Pharmaceuticals, O. Zubsolv Sublingual Films. 2015 [cited 2015 8\/1\/2015]; Available from: https:\/\/www.zubsolv.com\/ ."},{"key":"518_CR16","unstructured":"Biodelivery Sciences International, I. Bunivail buccal film. 2015 [cited 2015 8\/5\/2015]."},{"issue":"4","key":"518_CR17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5055\/jom.2014.0215","volume":"10","author":"S Colameco","year":"2014","unstructured":"Colameco S, Pohl M. Buprenorphine in the workers\u2019 compensation setting. J Opioid Manag. 2014;10(4):277\u201383.","journal-title":"J Opioid Manag"},{"key":"518_CR18","unstructured":"Administration, S.A.a.M.H.S. Buprenorphine. 2012 [cited 2015 8\/10\/2015]; Available from: http:\/\/buprenorphine.samhsa.gov\/about.html ."},{"key":"518_CR19","unstructured":"Greene, P., Outpatient drug utilization trends for buprenorphine years 2002-2009, D.o.E.O.o.S.a.E.U.S.F.a.D. Administration, Editor. 2010, U.S. Food and Drug Administration."},{"key":"518_CR20","doi-asserted-by":"crossref","unstructured":"Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-9.","DOI":"10.1080\/02791072.2003.10400007"},{"key":"518_CR21","unstructured":"Administration, S.A.a.M.H.S. Buprenorphine. 2012 [cited 2015 8\/5\/2015]; Available from: http:\/\/buprenorphine.samhsa.gov\/about.html ."},{"issue":"2","key":"518_CR22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11606-008-0866-8","volume":"24","author":"JD Lee","year":"2009","unstructured":"Lee JD et al. Home buprenorphine\/naloxone induction in primary care. J Gen Intern Med. 2009;24(2):226\u201332.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"518_CR23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jsat.2010.12.002","volume":"40","author":"CO Cunningham","year":"2011","unstructured":"Cunningham CO et al. A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat. 2011;40(4):349\u201356.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"518_CR24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jsat.2004.06.005","volume":"27","author":"DA Fiellin","year":"2004","unstructured":"Fiellin DA et al. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27(2):153\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"46","key":"518_CR25","first-page":"1291","volume":"58","author":"Centers for Disease, C. and Prevention","year":"2009","unstructured":"Centers for Disease, C. and Prevention. HIV infection among injection-drug users\u201434 states, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009;58(46):1291\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"518_CR26","first-page":"443","volume":"64","author":"C Conrad","year":"2015","unstructured":"Conrad C et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone\u2014Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"518_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","volume":"35","author":"LE Sullivan","year":"2008","unstructured":"Sullivan LE et al. Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87\u201392.","journal-title":"J Subst Abuse Treat"},{"issue":"2-3","key":"518_CR28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.drugalcdep.2007.04.006","volume":"90","author":"J Rosado","year":"2007","unstructured":"Rosado J et al. Sublingual buprenorphine\/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend. 2007;90(2-3):261\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"518_CR29","first-page":"166","volume":"176","author":"NC Clark","year":"2002","unstructured":"Clark NC, Lintzeris N, Muhleisen PJ. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Med J Aust. 2002;176(4):166\u20137.","journal-title":"Med J Aust"},{"issue":"4","key":"518_CR30","doi-asserted-by":"crossref","first-page":"e1009","DOI":"10.1542\/peds.2014-0840","volume":"134","author":"MC Lovegrove","year":"2014","unstructured":"Lovegrove MC et al. Emergency hospitalizations for unsupervised prescription medication ingestions by young children. Pediatrics. 2014;134(4):e1009\u201316.","journal-title":"Pediatrics"},{"issue":"6","key":"518_CR31","doi-asserted-by":"crossref","first-page":"e1700","DOI":"10.1542\/peds.2012-1342","volume":"130","author":"HK Kim","year":"2012","unstructured":"Kim HK et al. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics. 2012;130(6):e1700\u20133.","journal-title":"Pediatrics"},{"issue":"7","key":"518_CR32","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1526-4637.2010.00877.x","volume":"11","author":"N Dasgupta","year":"2010","unstructured":"Dasgupta N et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010;11(7):1078\u201391.","journal-title":"Pain Med"},{"issue":"5","key":"518_CR33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/10550490903077820","volume":"18","author":"S Gwin Mitchell","year":"2009","unstructured":"Gwin Mitchell S et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18(5):346\u201355.","journal-title":"Am J Addict"},{"issue":"6","key":"518_CR34","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5055\/jom.2007.0018","volume":"3","author":"TJ Cicero","year":"2007","unstructured":"Cicero TJ, Surratt H, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3(6):302\u20138.","journal-title":"J Opioid Manag"},{"issue":"6","key":"518_CR35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","volume":"10","author":"MP Davis","year":"2012","unstructured":"Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209\u201319.","journal-title":"J Support Oncol"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-015-0518-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-015-0518-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-015-0518-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T15:46:16Z","timestamp":1567352776000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-015-0518-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1007\/s13181-015-0518-4","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,16]]}}}